Close Menu

Oxford Immunotec

Of the 28 companies in the 360 Index, six companies' share prices increased while the share values of 22 declined month over month.

Recent publications demonstrating the clinical utility of the CMV assay represent a step toward diversifying into different types of assays, the firm said.

The company said it continues to see the global tuberculosis market expanding, and it is investing in both commercial resources and R&D.

The diagnostic firms were the final companies in the coverage universe of 360Dx to present at the annual conference.

As a result of its collaboration with Quest Diagnostics, Oxford Immunotec is experiencing a surge in orders from physician offices for its interferon gamma release assay TB kits.

The firm is investing in commercial resources and research and development to capitalize on continued expansion in the global tuberculosis market, according to its CEO.

Of the 29 companies in the index, 16 firms' share prices retreated while the other 13 saw their stock prices rise month over month.

The firm said that it ended a distributor agreement that it had inked in 2013 with Fosun Long March Medical Science and Shanghai Xin Chang Medical Device.

Oxford Immunotec beat analysts' consensus estimates on the top and bottom lines as its second quarter net loss last year swung to a profit this year.

UK researchers said they are developing a commercial test that could enable sensitive detection of tuberculosis DNA in blood and provide an option to broaden screening. 

Pages